Compare Enveric Biosciences Inc (ENVB) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $70.47 (market cap $323.80B). The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is far larger — about 48400.6× Enveric Biosciences Inc's market cap, and Vanguard Tax Managed Fund FTSE Developed Markets ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Vanguard Tax Managed Fund FTSE Developed Markets ETF for 131 Days on average.
| ENVB | VEA | |
|---|---|---|
Market Cap | $6.69M | $323.80B |
Volume | 41,141 | 9,762,021 |
Sector | Health | — |
52-Week High | $10.80 | $73.79 |
52-Week Low | $1.27 | $58.90 |
Typical Hold Time | 14 Days | 131 Days |
Enterprise Value | -$1.60M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
VEA, the Vanguard FTSE Developed Markets ETF, trades at $70.26, down 1.2% on the day amid a bearish technical signal. The ETF provides cost-efficient exposure to developed markets outside the U.S., with a 0.03% expense ratio and competitive dividend yield. Recent news highlights institutional activity, with firms like Allianz Asset Management increasing stakes while others trimmed positions.
The outlook remains mixed, with technical indicators signaling caution but fundamental strengths in low costs and diversification. Key risks include global market volatility and currency fluctuations. Investors should weigh the ETF's stable, income-oriented profile against near-term bearish momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →
